Clinical trials: Gout and Hyperuricemia
Gout With Hyperuricemia in Adults
Clinical Study of HR091506 Tablets in Treatment of Gout With Hyperuricemia in Adults
The study is being conducted to evaluate the efficacy, and safety of HR091506 tablets for treatment of gout with hyperuricemia in adults, and to compare the results with febuxostat tablets in the same doses.
- Trial name
- NCT06139393
- Where
- China
- Volunteers
- 765 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Gout, Hyperuricemia
Purine Metabolism Enzyme SNP to Uric Acid Production
Determine whether a relationship exists between polymorphisms of the genes XDH, HPRT1, and PRPS1 and gout, hyperuricemia, or the dose of xanthine oxidase (XO) inhibitors to reach a goal serum uric acid of less than 6 mg/dL.
- Trial name
- NCT01830725
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Keesler Air Force Base Medical Center
Gout Disease
Combined Metabolic Activator Supplementation in Subjects Diagnosed With Gout
This will be a randomised, double-blind, placebo-controlled, multi-centre study with the aim to establish metabolic improvements in individuals diagnosed with hyperuricemia associated with gout by treatment with CMA2 including…
- Trial name
- NCT07889284
- Testing
- Combined metabolic activators, Collagen and maltodextrin
- Where
- 12 sites in Turkey (Türkiye)
- Volunteers
- 336 people
- Sponsor
- ScandiBio Therapeutics AB
Gout, Inflammatory Rheumatism
Treat-to-target by Email During Urate-lowering Therapy in Gout
Gout is secondary to urate crystal deposition after chronic elevation of serum urate level (SUL). Long-term lowering SUL below 360 µmol/L allows dissolution of deposited crystals and disease cure.
- Conditions
- Gout, Inflammatory Rheumatism, Hyperuricemia, Posology Adjustment
- Trial name
- GOUTEmail (NCT04733079)
- Testing
- Cleanweb electronic messaging ePro, Usual follow-up
- Where
- 2 sites in France
- Volunteers
- 204 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Gout
Safety/Efficacy Study to Evaluate of MBX-102 in Combination With Allopurinol in Gout Patients
The purpose of this study is to evaluate the efficacy, safety and tolerability of MBX-102 in combination with allopurinol compared to allopurinol alone when administered orally once a day for four weeks to gout patients with an…
- Trial name
- NCT01399008
- Testing
- Arhalofenate, Allopurinol, Colchicine
- Where
- 24 sites in United States, Canada and 1 more
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Gilead Sciences
Type 2 Diabetes Mellitus (T2DM), Type 2 Diabetes
Osaka Cardiometabolic Epidemiological Study: Ohtori Study Part 2
The aim of this study is to investigate the relationship between body fat distribution measured by CT scan and related risk factors with the risk of incident metabolic and cardiovascular disease in a prospective cohort study of…
- Conditions
- Type 2 Diabetes Mellitus (T2DM), Type 2 Diabetes, Diabetes Mellitus, Hypertension
- Trial name
- OCES-2 (NCT06694012)
- Where
- Japan
- Volunteers
- 2,000 people
- Sponsor
- Osaka Metropolitan University
Hyperuricemia, Gout
An Inpatient Study of ALLN-346 (Engineered Urate Oxidase) in Hyperuricemic Subjects (Study 201)
The purpose of this Phase IIa study is to evaluate the safety and tolerability of ALLN-346 in subjects with hyperuricemia in an inpatient, controlled setting.
- Conditions
- Hyperuricemia, Gout, Chronic Kidney Diseases
- Trial name
- NCT04987242
- Testing
- ALLN-346
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Allena Pharmaceuticals
Hyperuricemia, Gout
Safety, Tolerability and Pharmacokinetic/Pharmacodynamic Characteristics of LC350189
This will be a dose block-randomized, double-blind, active and placebo controlled, single and multiple dosing, dose-escalation study to evaluate tolerability, safety and pharmacokinetic / pharmacodynamic characteristics.
- Trial name
- NCT01361646
- Testing
- LC350189
- Where
- South Korea
- Volunteers
- 129 people, healthy volunteers welcome
- Sponsor
- LG Life Sciences
Hyperuricemia, Gout
Safety and Efficacy Study of MBX-102 in Treatment of Hyperuricemia in Patients With Gout
The purpose of the study is to evaluate the safety and effectiveness of MBX-102 compared to placebo when given orally once daily for 4 weeks for the treatment of hyperuricemia in patients with gout.
- Trial name
- NCT01336686
- Testing
- Arhalofenate, Colchicine
- Where
- 12 sites in United States
- Volunteers
- 67 people
- Sponsor
- Gilead Sciences
Hyperuricemia or Gout, Nephrolithiasis
Exploratory Study on the Treatment of Gout With Potassium Citrate Sustained-release Tablets
To evaluate whether alkalization has the effect of lowering uric acid and reducing gout flare and determine whether alkalization has a role in the prevention and treatment of urinary calculi in gout, the research participants…
- Trial name
- NCT06966635
- Testing
- Sodium Bicarbonate Oral Capsule, Potassium Citrate Tablets, uric-acid-lowering drug
- Where
- China
- Volunteers
- 312 people
- Sponsor
- Huashan Hospital
Gout
Effects of Hyperuricemia Reversal on Features of the Metabolic Syndrome
This study is being done to evaluate whether the medication, febuxostat, can improve the degree of insulin resistance and other features of the metabolic syndrome (high blood pressure, elevated insulin levels, excess body fat…
- Trial name
- NCT01654276
- Testing
- Febuxostat
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Texas Southwestern Medical Center